Alumis Inc. (ALMS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $21.52: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a second-generation allosteric inhibitor with positive Phase 3 data in plaque psoriasis (Jan 2026) and Phase 2b ongoing in SLE, plus A-005, a CNS-penetrant TYK2 inhibitor in... Read more
Sell if holding. Engine safety override at $21.52: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 8/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, news boost analyst cluster(5), earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Alumis Inc.
Latest news
- Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40 — benzinga May 19, 2026 positive
- This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday — benzinga May 15, 2026 positive
- Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51 — benzinga May 15, 2026 positive
- Guggenheim Maintains Buy on Alumis, Raises Price Target to $34 — benzinga May 15, 2026 positive
- This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday — benzinga May 15, 2026 negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineenvu10-K Item 1A: 'Our ability to achieve profitability in the future is dependent upon obtaining regulatory approval for and successfully commercializing our most advanced candidate, envu'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.52: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $20.02. Score 5.2/10, moderate confidence.
Take-profit target: $34.71 (+61.3% upside). Prior stop was $20.02. Stop-loss: $20.02.
Concentration risk — Pipeline: envu; Quality below floor (2.9 < 4.0); Value-trap signals (2/5): High leverage (D/E 2.8), Material insider selling (125 sells, 0.03% of cap).
Alumis Inc. trades at a P/E of N/A (forward -7.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ALMS with a consensus score of 4.4/5. Average price target: $40.
What does Alumis Inc. do?Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a...
Alumis is a clinical-stage biopharmaceutical company developing TYK2 inhibitors: envu (envudeucitinib), a second-generation allosteric inhibitor with positive Phase 3 data in plaque psoriasis (Jan 2026) and Phase 2b ongoing in SLE, plus A-005, a CNS-penetrant TYK2 inhibitor in Phase 1. The company has no approved products and no revenue.